REFERENCES
  1. Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2013;170:1-7.
  2. Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol. 2011;25:391-403.
  3. Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol. 2013;209:544.e1-12.
  4. Steegers EAP, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376:631-44.
  5. Chappell LC, Cluver CA, Kingdom J, Tong S. Pre-eclampsia. Lancet. 2021;398:341-54.
  6. Hofmeyr GJ, Lawrie TA, Atallah ÁN, Torloni MR. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2018;10:CD001059.
  7. Ceulemans M, Van Calsteren K, Allegaert K, Foulon V. Health products’ and substance use among pregnant women visiting a tertiary hospital in Belgium: A cross-sectional study. Pharmacoepidemiol Drug Saf. 2019;28:1231-8.
  8. Meyer A, Fermaut M, Drouin J, Carbonnel F, Weill A. Drug use for gastrointestinal symptoms during pregnancy: A French nationwide study 2010-2018. PLoS One. 2021;16:e0245854.
  9. Onda K, Tong S, Beard S, Binder N, Muto M, Senadheera SN, et al. Proton pump inhibitors decrease soluble fms-like tyrosine kinase-1 and soluble endoglin secretion, decrease hypertension, and rescue endothelial dysfunction. Hypertension. 2017;69:457-68.
  10. Saleh L, Samantar R, Garrelds IM, van den Meiracker AH, Visser W, Danser AHJ. Low soluble fms-like tyrosine kinase-1, endoglin, and endothelin-1 levels in women with confirmed or suspected preeclampsia using proton pump inhibitors. Hypertension. 2017;70:594-600.
  11. Hastie R, Bergman L, Cluver CA, Wikman A, Hannan NJ, Walker SP, et al. Proton pump inhibitors and preeclampsia risk among 157 720 women. Hypertension. 2019;73:1097-103.
  12. Bello NA, Huang Y, Syeda SK, Wright JD, D’Alton ME, Friedman AM. Receipt of proton-pump inhibitors during pregnancy and risk for preeclampsia. Am J Perinatol. 2021;38:1519-25.
  13. Choi A, Noh Y, Park SH, Choe SA, Shin JY. Exploration of proton pump inhibitors use during pregnancy and preeclampsia. JAMA Netw Open. 2021;4:e2124339.
  14. Van Gelder MMHJ, Bretveld RW, Roukema J, Steenhoek M, van Drongelen J, Spaanderman MEA, et al. Rationale and design of the PRegnancy and Infant DEvelopment (PRIDE) Study. Paediatr Perinat Epidemiol. 2013;27:34-43.
  15. Van Gelder MMHJ, Merkus PJFM, van Drongelen J, Swarts JW, van de Belt TH, Roeleveld N. The PRIDE Study: Evaluation of online methods of data collection. Paediatr Perinat Epidemiol. 2020;34:484-94.
  16. Vorstenbosch S, te Winkel B, van Gelder MMHJ, Kant A, Roeleveld N, van Puijenbroek E. Aim and design of pREGnant, the Dutch Pregnancy Drug Register. Drug Saf. 2019;42:1-12.
  17. Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018;17:530-8.
  18. Von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy. 2003;22:143-8.
  19. De Boer J, Zeeman K, Verhoeven C. [KNOV guideline: Hypertensive disorders during pregnancy, delivery, and puerperium] [Internet]. Utrecht: Koninklijke Nederlandse Organisatie van Verloskundigen; c2012 [cited 2022 Mar 25]. Available from: https://assets.knov.nl/p/557056/none/PDF%20Vakkennis/KNOV_Standaard_Hypertensie_versie2012.pdf. Dutch.
  20. Beekers P, Jamaladin H, van Drongelen J, Roeleveld N, van Gelder MMHJ. Data from web-based questionnaires were valid for gestational diabetes and preeclampsia, but not gestational hypertension. J Clin Epidemiol. 2020;125:84-90.
  21. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2022 [Internet]. Oslo: Norwegian Institute of Public Health; c2021 [cited 2022 Mar 25]. Available from: https://www.whocc.no/atc_ddd_index/.
  22. Van Gelder MMHJ, Vorstenbosch S, te Winkel B, van Puijenbroek EP, Roeleveld N. Using web-based questionnaires to assess medication use during pregnancy: A validation study in 2 prospectively enrolled cohorts. Am J Epidemiol. 2018;187:326-36.
  23. Wood ME, Lupattelli A, Palmsten K, Bandoli G, Hurault-Delarue C, Damase-Michel C, et al. Longitudinal methods for modeling exposures in pharmacoepidemiologic studies in pregnancy. Epidemiol Rev. 2021;43:130-46.
  24. Genolini C, Falissard B. KmL: a package to cluster longitudinal data. Comput Methods Programs Biomed. 2011;104:e112-21.
  25. Genolini C, Alacoque X, Sentenac M, Arnaud C. kml and kml3d: R packages to cluster longitudinal data. J Stat Softw. 2015;65:1-34.
  26. Palmsten K, Rolland M, Hebert MF, Clowse MEB, SChatz M, Xu R, et al. Patterns of prednisone use during pregnancy in women with rheumatoid arthritis: Daily and cumulative dose. Pharmacoepidemiol Drug Saf. 2018;27:430-8.
  27. Matok I, Azoulay L, Yin H, Suissa S. Immortal time bias in observational studies of drug effects in pregnancy. Birth Defects Res A Clin Mol Teratol. 2014;100:658-62.
  28. Platt RW, Hutcheon JA, Suissa S. Immortal time bias in epidemiology. Curr Epidemiol Rep. 2019;6:23-7.
  29. Palmsten K, Bandoli G, Watkins J, Vazquez-Benitez G, Gilmer TP, Chambers CD. Oral corticosteroids and risk of preterm birth in the California Medicaid program. J Allergy Clin Immunol Pract. 2021;9:375-84.e5.
  30. Textor J, Hardt J, Knüppel S. DAGitty: a graphical tool for analyzing causal diagrams. Epidemiology. 2011;22:745.
  31. Bandoli G, Palmsten K, Flores KF, Chambers CD. Constructing causal diagrams for common perinatal outcomes: Benefits, limitations and motivating examples with maternal antidepressant use in pregnancy. Paediatr Perinat Epidemiol. 2016;30:521-8.
  32. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159:702-6.
  33. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc. 1989;84:1074-8.
  34. Zou GY, Donner A. Extension of the modified Poisson regression model to prospective studies with correlated binary data. Stat Methods Med Res. 2013;22:661-70.
  35. Howe CJ, Cole SR, Lau B, Napravnik S, Eron JJ Jr. Selection bias due to loss to follow up in cohort studies. Epidemiology. 2016;27:91-7.
  36. Syngelaki A, Bredaki FE, Vaikousi E, Maiz N, Nicolaides KH. Body mass index at 11-13 weeks’ gestation and pregnancy complications. Fetal Diagn Ther. 2011;30:250-65.
  37. Meertens LJE, Scheepers HCJ, van Kuijk SMJ, Aardenburg R, van Dooren IMA, Langenveld J, et al. External validation and clinical usefulness of first trimester prediction models for the risk of preeclampsia: A prospective cohort study. Fetal Diagn Ther. 2019;45:381-93.
  38. Chen Q, Zhang Y, Tong M, Wu M, Snowise S, Stone P, et al. Pre-treatment with calcium prevents endothelial cell activation induced by multiple activators, necrotic trophoblastic debris or IL-6 or preeclamptic sera: possible relevance to the pathogenesis of preeclampsia. Placenta. 2013;34:1196-201.
  39. Sukonpan K, Phupong V. Serum calcium and serum magnesium in normal and preeclamptic pregnancy. Arch Gynecol Obstet. 2005;273:12-6.
  40. Jain S, Sharma P, Kulshreshtha S, Mohan G, Singh S. The role of calcium, magnesium, and zinc in pre-eclampsia. Biol Trace Elem Res. 2010;133:162-70.
  41. Mackillop L. Pre-eclampsia: reducing the risk with calcium supplements. BMJ Clin Evid. 2015;12:1402.
  42. Santorelli G, Whitelaw D, Farrar D, West J, Lawlor DA. Associations of maternal vitamin D, PTH and calcium with hypertensive disorders of pregnancy and associated adverse perinatal outcomes: Findings from the Born in Bradford cohort study. Sci Rep. 2019;9:1205.
  43. Forde H, Crowley RK, McKenna MJ, Kilbane MT, Conway M, McDonnell CM, et al. No effect of calcium and vitamin D intake on maternal blood pressure in a healthy pregnant population. Eur J Obstet Gynecol Reprod Biol. 2021;264:8-14.
  44. Xu R, Luo Y, Chambers C. Assessing the effect of vaccine on spontaneous abortion using time-dependent covariates Cox models. Pharmacoepidemiol Drug Saf. 2012;21:844-50.
  45. Daniel S, Koren G, Lunenfeld E, Levy A. Immortal time bias in drug safety cohort studies: spontaneous abortion following nonsteroidal antiinflammatory drug exposure. Am J Obstet Gynecol. 2015;212:307.e1-6.
  46. Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler H, et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol. 2012;206:58.e1-8.
  47. Sibai BM, Stella CL. Diagnosis and management of atypical preeclampsia-eclampsia. Am J Obstet Gynecol. 2009;200:481.e1-7.
  48. Andrade SE, Bérard A, Nordeng HME, Wood ME, van Gelder MMHJ, Toh S. Administrative claims data versus augmented pregnancy data for the study of pharmaceutical treatments in pregnancy. Curr Epidemiol Rep. 2017:4;106-16.
  49. Nohr EA, Frydenberg M, Henriksen TB, Olsen J. Does low participation in cohort studies induce bias? Epidemiology. 2006;17:413-8.
  50. Nilsen RM, Vollset SE, Gjessing HK, Skjærven R, Melve KK, Schreuder P, et al. Self-selection and bias in a large prospective pregnancy cohort in Norway. Paediatr Perinat Epidemiol. 2009;23:597-608.
  51. Hatch EE, Hahn KA, Wise LA, Mikkelsen EM, Kumar R, Fox MP, et al. Evaluation of selection bias in an internet-based study of pregnancy planners. Epidemiology. 2016;27:98-104.
  52. Biele G, Gustavson K, Czajkowski NO, Nilsen RM, Reichborn-Kjennerud T, Magnus PM, et al. Bias from self selection and loss to follow-up in prospective cohort studies. Eur J Epidemiol. 2019;34:927-38.
  53. Thélin CS, Richter JE. Review article: the management of heartburn during pregnancy and lactation. Aliment Pharmacol Ther. 2020;51:421-34.